Trials / Completed
CompletedNCT00190983
A Trial for Patients With Advanced/Recurrent Cervical Cancer
A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed | Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression. |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2005-09-19
- Last updated
- 2009-11-20
- Results posted
- 2009-08-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00190983. Inclusion in this directory is not an endorsement.